Inhibrx Profit margin
What is the Profit margin of Inhibrx?
The Profit margin of Inhibrx, Inc. is -13,408.94%
What is the definition of Profit margin?
Profit margin is a measure of profitability and is calculated by finding the net profit as a percentage of the revenue.
lfy (last fiscal year)
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Profit margin of companies in the Health Care sector on NASDAQ compared to Inhibrx
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Companies with profit margin similar to Inhibrx
- Magmatic Resources has Profit margin of -13,870.37%
- Burley Minerals Ltd has Profit margin of -13,818.45%
- Rafaella Resources has Profit margin of -13,804.35%
- Loop Industries Inc has Profit margin of -13,782.35%
- Organovo Inc has Profit margin of -13,459.63%
- Organovo Hldgs Dl ,01 has Profit margin of -13,458.72%
- Inhibrx has Profit margin of -13,408.94%
- Bio-Gene Technology has Profit margin of -13,388.89%
- Equatorial Resources has Profit margin of -13,379.84%
- Ovid Therapeutics Inc has Profit margin of -13,362.17%
- Global Oil & Gas has Profit margin of -13,032.26%
- Youth Champ has Profit margin of -13,000.00%
- BioXcel Therapeutics Inc has Profit margin of -12,974.86%